The Bio-Europe Spring conference in Berlin serves as a hub for biopharmaceutical companies to discuss partnerships and collaborate on research. This year, the event attracted many startups working on cutting-edge research in areas such as monoclonal antibodies, AI, central nervous system therapeutics, and microbiome studies. One notable winner was Nionyx Bio, which showcased its AAV capsid platform for gene therapies targeting kidney disease. The conference also emphasized the potential of Europ...